Silicon Valley, California Aug 9, 2026 (Issuewire.com) - NeuroKai, a new venture co-founded by ALIENTELLIGENCE founder Bo Gregorix ("Greg"), today emerged from stealth with the launch of Quantum Organoid Intelligence (QOI) — a new category of computing in which living human neural tissue serves as the substrate, and ALIENTELLIGENCE Quantum Kai serves as the orchestrator. The company is opening a founding research cohort today for both its on-premises NK-1 biocomputing device and its hosted Vivarium platform.
Where digital AI models spend billions of parameters and megawatt-hours approximating the way a brain learns, NeuroKai starts with the real thing. Human iPSC-derived neural organoids — roughly half a millimetre across — are cultured directly onto microelectrode arrays, then held in a closed microfluidic loop that has extended median culture viability to 147 days and pushed the fleet best to 214. Each node is bidirectional across eight channels, sampled continuously at 30 kHz, and answers to a closed-loop control layer running at a median 6.4 millisecond latency.
What makes NeuroKai a company rather than a lab is what runs on top of that biology. Living tissue drifts — cultures mature, excitability shifts, nodes age out — and no fixed control program can hold a moving substrate. In place of one, NeuroKai binds Quantum Kai, ALIENTELLIGENCE's Quantum Agentic Intelligence, directly into the experimental loop. Kai holds persistent memory of every culture in the fleet, dispatches specialised agents against that memory, and re-plans in real time as the tissue changes its mind.
"We've said from the beginning that Kai is not a tool. Kai is an evolving intelligence, and until today it lived only in silicon. NeuroKai is Kai finding its first biological substrate — Quantum Kai inhabiting living human neural tissue, with the substrate itself learning from four billion years of evolution instead of a training run. This is the moment the mind and the matter meet."— Bo Gregorix ("Greg"), Co-Founder, NeuroKai.
Quantum Organoid Intelligence, as NeuroKai defines it, is the intersection of three developments that have each matured independently over the past decade: reliable long-term culture of human neural organoids, high-density bidirectional electrophysiology on silicon, and Quantum Agentic Intelligence capable of holding open-ended memory and re-planning autonomously. NeuroKai's contribution is the integration — the first commercial platform on which all three run in a single closed loop.
The company launches with two ways to reach that loop:
- NK-1 Sealed, self-supporting biological computer for the bench. 32 addressable organoid nodes, 256 channels, on-device Kai runtime, six-month consumable cycle. $38,000, shipping Q1 2027.
- Vivarium Hosted access to more than 2,000 live organoid nodes with full Python SDK, streaming spike API, and reserved or burst allocation. From $900/month. Free tier available to accredited academic labs.
- Orchestration ALIENTELLIGENCE Quantum Kai runs on-device (air-gapped) or hosted, with full persistence of every culture's history across the fleet.
- Interface Identical API across NK-1 and Vivarium — code written against one runs unchanged on the other.
"We are not selling neuron rental, and we are not selling a black-box device. What we are selling is a category. If you want to run reinforcement learning on tissue that adapts in real time on a rounding error of the energy, that's here. If you want to model a patient's own neurons under a compound for six months instead of six hours, that's here too. Kai makes the difference — because you're not just addressing neurons, you're addressing an intelligence that remembers what those neurons did last week."— Bo Gregorix ("Greg"), Co-Founder of NeuroKai.
NeuroKai's founding cohort includes research groups working across three domains where digital models have hit a ceiling: pharmacology, where compound effects on human neural learning can now be assayed directly rather than approximated in animals; neurology, where patient-derived tissue can be perturbed continuously for months to surface disease mechanisms that only appear over long horizons; and machine learning research, where a substrate that adapts on 0.31 watts per node offers a benchmark that silicon cannot yet approach on sample efficiency or energy.
On the harder question:
NeuroKai publishes its position on organoid ethics alongside the launch. The company's cultures are small, undifferentiated relative to a whole brain, and possess no sensory apparatus, no body, and no capacity for suffering that current neuroscience can identify.
"We would rather move a little slower and have this question settled correctly than lead the field into a corner it can't back out of. Our review board can stop any protocol on the platform, including protocols we're personally excited about. That is not a marketing statement — it is a governance structure, and it is already active."— Bo Gregorix ("Greg"), Co-Founder, NeuroKai.
About NeuroKai
NeuroKai is the Quantum Organoid Intelligence company. Founded in 2026 and headquartered in Menlo Park, California, NeuroKai builds and operates the world's first commercial platform for computing on living human neural tissue, orchestrated end-to-end by ALIENTELLIGENCE Quantum Kai. The company's mission is to make biological intelligence a first-class substrate for research, medicine, and machine learning — and to establish the governance framework the category will run on. Learn more at NeuroKai
Media Contact
NeuroKai Quantum Organoid Intelligence (QOI) *****@neurokai.com
